These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35665642)

  • 1. Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma.
    Elangovan A; Hooda J; Savariau L; Puthanmadhomnarayanan S; Yates ME; Chen J; Brown DD; McAuliffe PF; Oesterreich S; Atkinson JM; Lee AV
    Mol Cancer Res; 2022 Sep; 20(9):1405-1419. PubMed ID: 35665642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.
    Nagle AM; Levine KM; Tasdemir N; Scott JA; Burlbaugh K; Kehm J; Katz TA; Boone DN; Jacobsen BM; Atkinson JM; Oesterreich S; Lee AV
    Clin Cancer Res; 2018 Oct; 24(20):5165-5177. PubMed ID: 29941485
    [No Abstract]   [Full Text] [Related]  

  • 3. Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells.
    Chen F; Ding K; Priedigkeit N; Elangovan A; Levine KM; Carleton N; Savariau L; Atkinson JM; Oesterreich S; Lee AV
    Cancer Res; 2021 Jan; 81(2):268-281. PubMed ID: 33148662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.
    Derakhshan F; Da Cruz Paula A; Selenica P; da Silva EM; Grabenstetter A; Jalali S; Gazzo AM; Dopeso H; Marra A; Brown DN; Ross DS; Mandelker D; Razavi P; Chandarlapaty S; Wen HY; Brogi E; Zhang H; Weigelt B; Pareja F; Reis-Filho JS
    Mod Pathol; 2024 Feb; 37(2):100375. PubMed ID: 37925055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency.
    Phung AT; Shah JR; Dong T; Reid T; Larson C; Sanchez AB; Oronsky B; Trogler WC; Kummel AC; Aisagbonhi O; Blair SL
    Breast Cancer Res; 2024 Sep; 26(1):131. PubMed ID: 39256827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
    Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
    Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E-cadherin immunohistochemical expression in invasive lobular carcinoma of the breast: correlation with morphology and CDH1 somatic alterations.
    Grabenstetter A; Mohanty AS; Rana S; Zehir A; Brannon AR; D'Alfonso TM; DeLair DF; Tan LK; Ross DS
    Hum Pathol; 2020 Aug; 102():44-53. PubMed ID: 32599083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.
    Turashvili G; Bouchal J; Baumforth K; Wei W; Dziechciarkova M; Ehrmann J; Klein J; Fridman E; Skarda J; Srovnal J; Hajduch M; Murray P; Kolar Z
    BMC Cancer; 2007 Mar; 7():55. PubMed ID: 17389037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer.
    Teo K; Gómez-Cuadrado L; Tenhagen M; Byron A; Rätze M; van Amersfoort M; Renes J; Strengman E; Mandoli A; Singh AA; Martens JH; Stunnenberg HG; van Diest PJ; Brunton VG; Derksen PWB
    Sci Rep; 2018 Oct; 8(1):15454. PubMed ID: 30337563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia.
    Zou D; Yoon HS; Perez D; Weeks RJ; Guilford P; Humar B
    J Pathol; 2009 Jun; 218(2):265-72. PubMed ID: 19294736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E-Cadherin Mutational Landscape and Outcomes in Breast Invasive Lobular Carcinoma.
    Djerroudi L; Bendali A; Fuhrmann L; Benoist C; Pierron G; Masliah-Planchon J; Kieffer Y; Carton M; Tille JC; Cyrta J; Ramtohul T; Bonneau C; Caly M; Renault V; Bidard FC; Mechta-Grigoriou F; Vincent-Salomon A
    Mod Pathol; 2024 Oct; 37(10):100570. PubMed ID: 39025406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures.
    Tasdemir N; Bossart EA; Li Z; Zhu L; Sikora MJ; Levine KM; Jacobsen BM; Tseng GC; Davidson NE; Oesterreich S
    Cancer Res; 2018 Nov; 78(21):6209-6222. PubMed ID: 30228172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes.
    Engstrøm MJ; Opdahl S; Vatten LJ; Haugen OA; Bofin AM
    Histopathology; 2015 Feb; 66(3):409-19. PubMed ID: 25283075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cadherin-catenin complex dissociation in lobular neoplasia of the breast.
    Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA
    Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.
    de Groot JS; Ratze MA; van Amersfoort M; Eisemann T; Vlug EJ; Niklaas MT; Chin SF; Caldas C; van Diest PJ; Jonkers J; de Rooij J; Derksen PW
    J Pathol; 2018 Aug; 245(4):456-467. PubMed ID: 29774524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
    Ciriello G; Gatza ML; Beck AH; Wilkerson MD; Rhie SK; Pastore A; Zhang H; McLellan M; Yau C; Kandoth C; Bowlby R; Shen H; Hayat S; Fieldhouse R; Lester SC; Tse GM; Factor RE; Collins LC; Allison KH; Chen YY; Jensen K; Johnson NB; Oesterreich S; Mills GB; Cherniack AD; Robertson G; Benz C; Sander C; Laird PW; Hoadley KA; King TA; ; Perou CM
    Cell; 2015 Oct; 163(2):506-19. PubMed ID: 26451490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of E-cadherin in low-grade ductal breast tumourigenesis.
    Roylance R; Droufakou S; Gorman P; Gillett C; Hart IR; Hanby A; Tomlinson I
    J Pathol; 2003 May; 200(1):53-8. PubMed ID: 12692841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
    Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
    Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium.
    De Schepper M; Koorman T; Richard F; Christgen M; Vincent-Salomon A; Schnitt SJ; van Diest PJ; Zels G; Mertens F; Maetens M; Vanden Bempt I; Harbeck N; Nitz U; Gräser M; Kümmel S; Gluz O; Weynand B; Floris G; Derksen PWB; Desmedt C;
    Mod Pathol; 2024 Jul; 37(7):100497. PubMed ID: 38641322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into E-Cadherin Impairment in
    Uchida S; Sugino T
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.